Sofgen Pharma S.A. Receivables

Sofgen Pharma S.A. (PROCF) currently reports a receivables of $170M as of September 2023. That compares with $160M in the prior-year period — up 4.1% year over year. Use the charts on this page to explore Sofgen Pharma S.A.'s receivables history and peer comparisons.

Sofgen Pharma S.A.'s receivables increased from $160M to $170M — a 4.1% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sofgen Pharma S.A. reported $170M in receivables as of September 2023. That compares with $160M in the prior-year period — up 4.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $170M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sofgen Pharma S.A., and consider following PROCF for alerts when major investors trade the stock.

Sofgen Pharma S.A. is classified in the Healthcare sector. On receivables, it currently shows $170M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PROCF with unrelated industries.